Aldeyra Therapeutics
ALDX
35 hedge funds and large institutions have $66.4M invested in Aldeyra Therapeutics in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 3 closing their positions.
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
91% more capital invested
Capital invested by funds: $34.7M → $66.4M (+$31.7M)
35% more funds holding
Funds holding: 26 → 35 (+9)
0.05% more ownership
Funds ownership: 49.16% → 49.2% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.32M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.62M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.44M |
| 4 |
PA
Perceptive Advisors
New York
|
+$1.04M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$878K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$454K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$225K |
| 3 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$62.7K |
| 4 |
BlackRock
New York
|
-$9.8K |
| 5 |
NFG
Next Financial Group
Houston,
Texas
|
-$9K |
ALDX Hedge Fund Activity: Q3 2017 in Review
35 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2017, worth a combined $66.4M — up 91% from $34.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ALDX positions and 3 closed out — a net gain of 10 holders — while 15 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.32M. The largest seller was Sabby Management, exiting entirely with an estimated $454K sold.
- 35 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2017, up from 26 in Q2 2017.
- Funds reported $66.4M of Aldeyra Therapeutics stock for Q3 2017, up 91% quarter-over-quarter.
- 13 funds opened new Aldeyra Therapeutics positions in Q3 2017 and 3 closed out, a net change of +10 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2017 was Millennium Management, an estimated $2.32M added.
- The largest Aldeyra Therapeutics seller in Q3 2017 was Sabby Management, an estimated $454K sold.
Based on aggregated 13F filings for Q3 2017.